It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
A small number of cases of myocarditis (inflammation of the heart muscle) and/or pericarditis (inflammation of the lining around the heart) following immunization with COVID-19 vaccines have been reported in Canada and internationally, including Israel, the United States (U.S.) and Europe. These cases are rare and most reported cases to date have followed vaccination with an mRNA vaccine (Pfizer-BioNTech/Comirnaty and Moderna/Spikevax) and resolved with symptomatic therapy within days
Current data from Alberta’s AEFI surveillance system does not support the need for a similar shift, and at this time younger Albertans can get either the Pfizer vaccine or the Moderna vaccine with informed consent.
Most cases had mild illness, responded well to usual medical treatment and rest, and their symptoms improved quickly. No long-term data is available yet.
The myocarditis/pericarditis incidence rate for the post-SPX cohort was 463 per 100,000 (95% CI 150–1079 per 100,000).
when compared to the published background rate of MP in a comparable population of service members not exposed to SPX immunization (detailed in Table 3), the relative risk of clinical MP was 214 fold higher (95% CI (65–558); p